Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
16.10
+1.17 (7.84%)
At close: Jun 26, 2026, 4:00 PM EDT
15.45
-0.65 (-4.04%)
After-hours: Jun 26, 2026, 7:40 PM EDT
Company Description
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy.
It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Vor Biopharma Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Jean-Paul Kress |
Contact Details
Address: 500 Boylston Street , Suite 1350 Boston, Massachusetts 02116 United States | |
| Phone | 617 655 6580 |
| Website | vorbio.com |
Stock Details
| Ticker Symbol | VOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001817229 |
| CUSIP Number | 929033207 |
| ISIN Number | US9290332074 |
| Employer ID | 81-1591163 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman, President and Chief Executive Officer |
| Sandesh Mahatme L.L.M. | Chief Business Officer and Chief Financial Officer |
| Dr. Robert Ang M.B.A., M.D., MBBS | Strategic Advisor |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder and Chairman of Scientific Advisory Board |
| Adi Osovsky | General Counsel |
| Carol Lincoln CCP | Head of Human Resources |
| Dallan Murray | Chief Commercial Officer |
| Dr. Navid Z. Khan Ph.D. | Chief Medical Affairs Officer |
| Dr. Jeremy Sokolove M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2026 | 8-K | Current Report |
| Jun 8, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | EFFECT | Notice of Effectiveness |
| May 6, 2026 | SCHEDULE 13G/A | Filing |
| May 6, 2026 | SCHEDULE 13G/A | Filing |
| May 1, 2026 | UPLOAD | Filing |
| Apr 27, 2026 | S-3 | Registration statement under Securities Act of 1933 |